Novltex: A new class of macrocyclic peptide antibiotics for treating bacterial pneumonia caused by Acinetobacter baumannii
Project title: Novltex: A dual-mechanism macrocyclic antibiotic for intravenous and inhaled treatment of carbapenem- and polymyxin-resistant Acinetobacter baumannii (CRAB) pneumonia
Carbapenem-resistant Acinetobacter baumannii (CRAB) is a major cause of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), which is difficult to treat and can be life-threatening. No new antibiotic chemical class with activity against A. baumannii has reached patients in over 50 years, while existing last-resort antibiotics may not reach the lungs effectively and can cause serious side-effects.
To address this need, the Singh laboratory at the University of Liverpool is developing Novltex, a new class of synthetic macrocyclic peptide antibiotics that bind to Lipid II, an essential building block that bacteria use to make their cell wall. Novltex compounds disrupt cell wall formation and can kill resistant strains of A. baumannii, including CRAB. Lipid II is a highly conserved, non-protein component that has remained essential to bacterial survival throughout evolution. By targeting this fundamental building block of the bacterial cell wall, Novltex is thought to present a high barrier to the development of antibiotic resistance.
The programme is at the lead optimisation stage, with demonstrated in vitro activity against CRAB and encouraging in vivo efficacy in a lung infection model. With funding and support from PACE, the team will optimise Novltex leads through iterative design–make–test cycles to understand how changes to the compounds affect their activity. The project will also explore the levels of compounds needed for effective treatment of CRAB in relevant infection models and improve properties that affect how long they might remain active in the body. The aim is to select one advanced lead and one differentiated backup for further development.
Success for the project will advance the development of Novltex as a new antibiotic for people with severe bacterial pneumonia caused by CRAB. In the longer term, this could provide an important new treatment option, reducing the reliance on existing antibiotics and, ultimately, helping to save lives. Treatment is expected to be delivered intravenously, but there is also potential for an inhaled approach that would improve delivery to the lung.

Company summary
Founded in 1881 as the original ‘red brick’, the University of Liverpool is one of the UK’s leading research-intensive higher education institutions with an annual turnover of £726.3 million, including an annual research income of £166 million.
Ranked in the top 140 universities worldwide in the QS World Rankings 2027, we are a member of the prestigious Russell Group of the UK’s leading research universities and have a global reach and influence that reflects our academic heritage as one of the country’s largest civic institutions.